ERBB2 and neoplasm: While wildtype HER2 overexpressed tumor cells were sensitive to HER2 inhibitors, those transformed cells by mutants like V777L, G776insYVMA and truncated isoform were less sensitive or resistant to HER2 inhibitor lapatinib [9, 16, 17].